Immunoglobulin G1 [247-alanine,248-glutamic acid,250-alanine,343-serine,344-serine,de-C-terminal-lysine], anti-(human T cell immunoreceptor with Ig and ITIM domains) (human monoclonal BMS-986207 ?1-chain), disulfide with human monoclonal BMS-986207 ?-chain, dimer
Ovarian Cancer
Compugen Ltdmonoclonal_antibodyPhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 59/ 100
Competitive context
525 Active assets in the Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tisotumab Vedotin Seagen Inc. | Phase 2 | BB |
TIL Inge Marie Svane | Phase 2 | BB |
Olaparib Shandong University | Phase 4 | BB |
Carboplatin Fudan University | Phase 4 | BB |
Irinotecan ARCAGY/ GINECO GROUP | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1 [247-alanine,248-glutamic acid,250-alanine,343-serine,344-serine,de-C-terminal-lysine], anti-(human T cell immunoreceptor with Ig and ITIM domains) (human monoclonal BMS-986207 ?1-chain), disulfide with human monoclonal BMS-986207 ?-chain, dimer is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →